A double-blind cross-over trial comparing trimethoprim-sulphamethoxazole with sulphamethoxazole in patients with chronic bronchitis in their usual state of health showed that the combination was more effective in reducing the volume and purulence of the sputum. Although the patients preferred treatment with the combination, there was no objective improvement in respiratory function. There was a significant incidence of side effects.
Trimethoprim
(2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine) has a high affinity for the enzyme dihydrofolate reductase in the bacterial cell (Roth, Falco, Hitchings, and Bushby, 1962) , an affinity 10,000-fold greater than for the mammalian enzyme. When trimethoprim is combined with sulphonamide, which acts in the same metabolic pathway by competing with the utilization of para-aminobenzoic acid, the combination is synergistic and bactericidal for a wide range of bacteria. The use of this drug combination has been reported in chest infections by Drew, Hughes, Fowle, and Cassell (1957) , Hughes (1968) , and Hughes, Drew, Johnson, and Jarvis (1968) . Hughes (1969) showed that trimethoprim-sulphamethoxazole was superior to ampicillin in the treatment of acute exacerbations of chronic bronchitis as assessed by changes in the bacterial content, purulence, and volume of the sputum, and the clinical response.
Most chemotherapy trials in chronic bronchitis have studied the changes in the purulence of the sputum and its bacterial content as well as the over-all clinical response (Stuart-Harris, 1968 Honcke, and Munkner (1967) , in a controlled study, found that chloramphenicol was of no greater benefit than physiotherapy or potassium iodide in patients with acute exacerbations when the response was assessed in terms of lung function. Howard (1967) and Howard and Astin (1969) Twenty-seven patients were allocated on a random basis to treatment with two tablets twice per day of either trimethoprim, 80 mg, plus sulphamethoxazole, 400 mg, or sulphamethoxazole, 500 mg. Each treatment period was 10 days and after an interval of four to six weeks the patient was treated with the alternative regime. The patients had all been under surveillance before the trial period and were seen between the two treatment periods. The majority have continued under observation. The patients were especially instructed not to use other antibiotics as most of them had reserve supplies at home. During the period of the trial other drug therapy was kept constant; in particular, the dose of prednisolone which one patient was receiving was maintained constant. The smoking habits of the patients did not change during the trial.
THE PATIENTS The patients, whose mean age was 59 (S.D.+9) years, were all outpatients in their usual state of health and most of them had attended the hospital with breathlessnes due to chronic bronchitis for years. All of them fulfilled the criteria for chronic bronchitis (Medical Research Council, 1965) Wheeze as a symptom The patient was asked to judge the severity of wheeze based on his own previous experience, and to classify the severity as mild, moderate, or severe. This was scored at each visit.
Cough The severity of cough was graded on its approximate time duration throughout the day: Grade I morning cough only Grade II cough throughout the day or night Grade III cough throughout both day and night.
Audible wheeze According to the area of distribution and the intensity of this sign, audible wheeze was graded as mild, moderate or severe.
Patient preference This was assessed at the end of the trial by asking the patient which course of treatment he preferred from the point of view of respiratory symptoms.
SPUTUM Changes in sputum purulence and volume were noted.
Purulence This was graded macroscopically according to the method proposed by Miller (1963) : M 1 pure mucoid specimen with no suspicion of pus M 2 predominantly mucoid specimen with a suspicion of pus P 1 purulent, grade 1, pus amounting to less than one-third of the specimen P 2 purulent, grade 2, pus amounting to one-third to two-thirds of the specimen P 3 purulent, grade 3, pus amounting to more than two-thirds of the specimen.
Volume The sputum produced in the first hour each day after rising from bed was collected in transparent plastic containers and the volume was compared with measured volumes in identical containers filled with coloured liquid. In only a few specimens did the volume of froth make the estimation of sputum volume difficult.
In assessing the change in sputum purulence and sputum volume a graph was constructed and the overall change in each 10-day period was assessed by inspection and this was checked by constructing regression lines. (Table I) .
Most of the patients did not improve with either form of treatment, but in some trimethoprim-sulphamethoxazole was significantly superior at the 5% level to sulphonamide in reducing sputum volume, sputum purulence, and cough. Significantly more patients preferred treatment with trimethoprim-sulphamethoxazole, presumably because of the reduction in the volume of sputum and the decreased cough.
When the volume of sputum was reduced by treatment this was almost always accompanied by a decrease in sputum purulence. This change usually occurred in patients with initially high sputum volume.
QUANTITATIVE ASSESSMENT It was possible to test whether:
(1) sulphamethoxazole significantly changed the average level of response in a 10-day period;
(2) trimethoprim-sulphamethoxazole significantly changed the average level of response in a 10-day period; and (3) the changes in the average level of responses differed significantly between two 10-day treatment periods.
The various responses, averaged over patients, are shown in Tables II, III The bacteriological results were not helpful in elucidating the therapeutic result further. There was a low rate of bacterial isolation which seems to be at variance with most reports of the isolation of pathogens from patients with chronic bronchitis. Angel, Fletcher, Hill and Tinker (1965) , however, reported that between illnesses they isolated H. influenzae and pneumococci from 21 % of patients with chronic bronchitis. The Sheffield patients had all received previous courses of oral antibiotics such as tetracycline and this may have influenced the frequency of bacterial isolation and the bacterial flora.
As the trial progressed, it was evident that one of the drugs was producing a higher incidence of side effects, effects suggestive of sulphonamide reactions and yet not encountered after sulphamethoxazole alone. This result suggested either that trimethoprim was itself responsible for these effects or that in some way trimethoprim promoted an increased sensitivity to sulphonamide. Such an incidence of side effects as that encountered is at variance with the low incidence reported by others (Drew et al., 1967; Hughes, 1968; Reeves, Faiers, Pursell, and Brumfitt, 1969; Gruneberg and Kolbe, 1969; Hughes et al., 1968; Hughes, 1969) . McCarthy (1969) reported neutropenia in patients with bronchitis treated with the combination. A case of reversible agranulocytosis was reported by Evans and Tell (1969) in a young woman, and this complication was heralded by fever, rigors, and generalized aches and pains which were later followed by an urticarial skin rash-a similar picture to that seen in one of the patients in this series.
Evidence of the role in infection in the deterioration in lung function in patients with chronic bronchitis may be obtained by relating the deterioration in the ventilatory capacity to the incidence of infective exacerbations, and also by studying the effect of chemoprophylaxis on lung function. Howard (1967) found some correlation between the magnitude of the regression coefficient and the number of acute exacerbations requiring antibiotic therapy. Yet in individual patients, acute chest illness had little effect on the overall pattern of the decline in the FEVo.75. Burrows and Earle (1969) could not relate information about recurrent respiratory infection obtained by a quarterly questionnaire to the course of the physiological findings or to survival in patients with chronic obstructive lung disease. Indeed, smoking appeared to be more significant in relation to deteriorating ventilatory capacity in these patients (Fletcher, 1968 ; Wilhelmsen, Orha, and Tibblin, 1969) . If bacterial infection has a clear role in the reduction of ventilatory function in these patients, then chemoprophylaxis, directed towards reducing the incidence and severity of acute infective exacerbations, should confer this benefit by decreasing the rate of deterioration in lung function. In the Medical Research Council (1966) trial the rate of decline of the FEV1 over a five-year period was unaffected by chemoprophylaxis, and this was confirmed by the findings of Calder, Lutz, and Schonell (1968) . Johnston et al. (1969) found that, although the average decline in the FEV1 over a five-year period of winter prophylaxis with tetracycline was less in treated patients, this was not statistically significant. In the present trial, a 10-day course of chemotherapy with trimethoprim-sulphamethoxazole reduced the volume and purulence of the sputum in a significant number of patients with chronic bronchitis. In spite of this, however, the various tests of lung function (FEVO 75, FVC,  PEFR, PaO2 and PaCO2) did not change significantly. The degree of benefit experienced by the treated patients must therefore remain in doubt. 
